View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
June 25, 2014updated 25 Nov 2021 10:14am

Ligand Pharma and TG Therapeutics sign licence agreement for IRAK-4 inhibitor programme

US-based Ligand Pharmaceuticals has signed an exclusive global licence agreement with TG Therapeutics to develop and commercialise Ligand’s interleukin-1 receptor associated kinase-4 (IRAK-4) inhibitors.

By Mekala ShivaramPrasad

US-based Ligand Pharmaceuticals has signed an exclusive global licence agreement with TG Therapeutics to develop and commercialise Ligand’s interleukin-1 receptor associated kinase-4 (IRAK-4) inhibitors.

Under the agreement, Ligand Pharmaceuticals will receive approximately $1m of TG Therapeutics common stock at the time of signing and will be eligible for $207m in milestones.

In addition, Ligand Pharmaceuticals is eligible to receive tiered royalties of 6%-9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.

“Given the evolution of these areas of research, there may be opportunities for treatment synergies between IRAK-4 inhibitors and these other programmes.”

Ligand Pharmaceuticals president and CEO John Higgins said: “TG Therapeutics has a proven ability in transitioning preclinical compounds into best-in-class clinical programmes and IRAK-4 is an ideal complement to their two clinical-stage hematology products, namely TG-1101, or ublituximab, and TGR-1202, a PI3K delta inhibitor.

“Given the evolution of these areas of research, there may be opportunities for treatment synergies between IRAK-4 inhibitors and these other programmes.”

IRAK-4, a serine/threonine protein kinase, is a key signalling component downstream of both toll-like receptors and interleukin-1 receptor suggesting that it may have therapeutic value for a range of autoimmune and inflammatory conditions.

According to Ligand Pharmaceuticals, recent pre-clinical studies suggest a potential that IRAK-4 plays an important role in certain b-cell lymphomas.

The company has identified orally available small molecule inhibitors of IRAK4, which are under investigation for use in cancer and autoimmune diseases.

The rights to the IRAK-4 programme were originally acquired by Ligand Pharmaceuticals at a discovery stage through the acquisition of Pharmacopeia in 2008.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU